Clinical Trials

Lung Cancer

At Lehigh Valley Health Network, we are committed to providing our patients and community with the best possible care and treatments. Our research scientists are integrated with our clinical departments for a comprehensive, collaborative approach to research. Have a question about clinical trials? Contact the Network Office of Research and Innovation at 610-402-9543.

Showing 10 of 23 Clinical Trials Related to Lung Cancer

Clinical Research Trial

KO-MEN-008

KO-MEN-008 A Study to Investigate the Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Doctor(s) Running This Study
Clinical Research Trial

Amgen 757 Lung Cancer

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306)

Clinical Research Trial

SWOG S1914 Lung Cancer

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC

Doctor(s) Running This Study
Clinical Research Trial

S2302 Pragmatica Lung

A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small

Doctor(s) Running This Study
Clinical Research Trial

S1827 Lung Cancer

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

Doctor(s) Running This Study
Clinical Research Trial

EA5181 Lung Cancer

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable

Doctor(s) Running This Study
Clinical Research Trial

A081801 Lung Cancer

INTEGRATION OF IMMUNOTHERAPY INTO ADJUVANT THERAPY FOR RESECTED NSCLC: ALCHEMIST CHEMO-IO (ACCIO)

Doctor(s) Running This Study